TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02943252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 500 mg in tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 40-60mg bid, days 1-14 , every 3 weeks
Study: NCT03784287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX 250
Description: Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
Study: NCT04315935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol and Propofol
Description: The two groups were given propofol for sedation, BG for butorphanol for analgesia and FG for fentanyl for analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl and Propofol
Description: Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
Study: NCT00989573

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo once-daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-6535
Description: oral administration of OPC-6535 25 mg once-daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-6535
Description: oral administration of OPC-6535 50 mg once-daily for 8 weeks
Study: NCT04059198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir soproxil
Description: Inarigivir soproxil 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir soproxil
Description: Inarigivir soproxil 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir soproxil
Description: Inarigivir soproxil 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate (TAF)
Description: Tenofovir alafenamide fumarate 25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate (TAF)
Description: Tenofovir alafenamide fumarate 25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate (TAF)
Description: Tenofovir alafenamide fumarate 25 mg tablet
Study: NCT04654884

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture (AA)
Description: The add-on treatment will be administered at the treatment sessions with their caregiver (i.e. registered nurse, psychologist, curator), and at each session the participants receive 5 sterile stainless needles in each outer ear. The needling is standardised according to the NADA-protocol. The needles will remain in the outer ears for approximately 45 minutes, and will be removed by the care giver.
Study: NCT02273518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER, new formulation I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER, new formulation II

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asasantin ER, present commercial formulation
Study: NCT03193125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: 500 mg tablets of L-Carnitine taken 3 times daily before meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg tablets of L-Carnitine taken 3 times daily before meals.
Study: NCT03750422

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Picoway
Description: 1064/532nm picosecond laser

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Picoway
Description: 1064/532nm picosecond laser

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stratacel
Description: a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties
Study: NCT03594656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ganoderma
Description: 0.8g twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganoderma
Description: 0.8g twice daily
Study: NCT04142658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-X Aortic Mechanical Valve
Description: Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-X Aortic Mechanical Valve
Description: Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
Study: NCT03594656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 0.8g twice daily
Study: NCT03303066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT04298333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injection, will be administered intramuscularly once per day. The cumulative dose range will be 0.64-1.12 mg/kg body weight depending on design level (design level 1-3). The daily dose range will be 0.02-0.035 mg/kg body weight (0.04-0.07 mL/kg) depending on design level (design level 1-3).~Dose level 1: 0.02 mg/kg body weight (0.04 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 2: 0.03 mg/kg body weight (0.06 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 3: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days.~Changes in the cumulative dose of BP-C1 between patients in the sequence are predefined and will be adjusted by escalation/deescalation rules based on changes in toxicity observed in the previous design level.~The duration of BP-C1 treatment will be 32 days.
Study: NCT03115463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration of oxygen during neonatal resuscitation
Description: Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Titration of oxygen during neonatal resuscitation
Description: Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
Study: NCT02356653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
Description: Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
Study: NCT03098706

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure control: normothermia
Description: Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure active
Description: Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
Study: NCT03139266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPLIFT
Description: Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: The control group will receive the recommendation to consider maintaining mental health services
Study: NCT03750422

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aquasonic
Description: clear ultrasound gel
Study: NCT02240290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tozadenant tablet
Description: Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
Study: NCT03933631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone acetate ophthalmic suspension 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone acetate ophthalmic suspension 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Description: Ofloxacin Drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin
Description: Ofloxacin Drops
Study: NCT01555424

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High dose
Description: This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference dose
Description: This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
Study: NCT00706537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active treatment
Description: 20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as two tablets once daily for three weeks
Study: NCT02440165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing nutrition intervention
Description: The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~* Information and advice;~* Examples of energy and protein rich meals;~* patients will be asked to register their nutritional intake for two days at home;~* after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care.
Study: NCT00832026

Intervention type: DEVICE
Intervention: Trans Nasal Insufflation (TNI) [nasal canula]
Description: Trans Nasal Insufflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.~By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing.
Study: NCT05007860

Intervention type: BIOLOGICAL
Intervention: PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
Description: Vaccines administered per standard of care

Intervention type: BIOLOGICAL
Intervention: PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
Description: Vaccines administered per standard of care

Intervention type: BIOLOGICAL
Intervention: PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
Description: Vaccines administered per standard of care
Study: NCT03422887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine administration during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen Axetil
Description: Flurbiprofen axetil administration during surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine and Flurbiprofen Axetil
Description: Nalbuphine and Flurbiprofen Axetil administration during surgery
Study: NCT04903769

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)
Description: SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.
Study: NCT03133377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early activity and mobilisation
Description: The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
Study: NCT01714063

Intervention type: DEVICE
Intervention: Pressurized Metered-Dose Inhaler
Description: Pressurized Metered-Dose Inhaler

Intervention type: DEVICE
Intervention: Pressurized Metered-Dose Inhaler
Description: Pressurized Metered-Dose Inhaler
Study: NCT02136355

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy plus Surgery
Description: Stereotactic body radiation therapy followed by surgical resection
Study: NCT02338557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motor relearning programme
Description: MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIRROR THERAPY
Description: Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
Study: NCT03063164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intralase IFS150
Description: Intralase flap creation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visumax
Description: Visumax flap creation
Study: NCT05912725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: 4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar~4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar
Study: NCT02240290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C14-tozadenant capsule
Description: Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
Study: NCT03300687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FX-322
Description: intratympanic injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intratympanic injection
Study: NCT01341405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: capsule, celecoxib 200 mg, once daily for 28 days
Study: NCT04346680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADSC administration
Description: The treated nerve will be identified and released. Scar tissue will be removed, and nerve fibers will be exposed. Prepared solutions of ADSC will be administered via microinjection with a 30-G needle along the released nerve fascicles, above and below the reconstructed area and around the adjacent tissue, which stayed in contact with the nerves.
Study: NCT02010034

Intervention type: DRUG
Group type: OTHER
Intervention: Omegaven
Description: Omegaven will be used in place of soy oil Intralipid
Study: NCT01199653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment
Description: Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative treatment with arm immobilised to a sling
Description: Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
Study: NCT04238962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by DV3396 pen-injector)
Description: Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide (administered by PDS290 pen-injector)
Description: Increasing doses of semaglutide given sc in the stomach for 7 weeks
Study: NCT01021501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifedipine controlled release tablets
Description: nifedipine controlled release tablets 60mg/day for at least 4 weeks
Study: NCT02284139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm EGF ointment 1ppm
Description: EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm EGF ointment 20 ppm
Description: EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arm Placebos
Description: EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
Study: NCT01182792

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C and E
Description: 1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 month Placebo
Study: NCT02569281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US-guided percutaneous electrolysis
Description: US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise
Description: An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
Study: NCT01391650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 'biomechanic of the knee'
Description: 20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
Study: NCT00794053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: detecting lymph node metastasis by staining
Description: this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
Study: NCT02178891

Intervention type: DEVICE
Group type: OTHER
Intervention: extra short implant
Study: NCT04191616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered intravenously over 30 ± 5 minutes, on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression. A dose of 20 mg/m\^2 will be administered on day 1 of cycle 1. All subsequent doses will be 56 mg/m\^2. The frequency of carfilzomib administration will be reduced to day 1 and 15 per cycle starting with cycle 13 and continued until progression or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at least 30 minutes, but no more than 4 hours prior to carfilzomib on days of carfilzomib administration. Dexamethasone will be administered at a dose of 40 mg on days 1, 8, 15, and 22 of each 28-day cycle up to progression during cycles 1 to 12. Dexamethasone will be administered at a dose of 20 mg on days 1 and 15 of each 28-day cycle up to progression during cycles 13 onward. For subjects more than or equal to 75 years of age, the dose will be 20 mg during cycles 1 through 12 and 10 mg from cycles 13 onward.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide dose will be 4 mg per day orally on days 1 to 21 of each cycle until progression.
Study: NCT04588558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flywheel exercise
Description: Flywheel training is a strength training modality that offers the possibility of performing exercises with eccentric overload and variable resistance as compared to conventional gravity-based resistance training. Flywheel exercise applied three days a week for 8 weeks
Study: NCT01912963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin